Beigene (NASDAQ:ONC – Get Free Report) is one of 1,070 publicly-traded companies in the “Pharmaceutical preparations” industry, but how does it contrast to its peers? We will compare Beigene to ...
CHMP recommends seven label expansions and one new approval, rejects Lilly Alzheimer's drug
CHMP backs label expansions for BMS's Opdivo, BeiGene's Tevimbra, AstraZeneca's Calquence & others; recommends approval of ...
The US biotech has just agreed a $2.7 billion deal with BeiGene that will give it a rapid route to rolling out its cancer drugs in China – both approved and in the development pipeline – as it ...
Bernstein raised the firm’s price target on BeiGene (ONC) to $259 from $207 and keeps a Market Perform rating on the shares. The firm sees more ...
In this article, we are going to take a look at where BeiGene, Ltd. (NASDAQ:ONC) stands against the other biotech stocks. No matter the market environment, you’ll always find entertainment in ...
BeiGene is an emerging Chinese biotechnology company with a global leading position in hematologic cancers thanks to its core drug Brukinsa. Since its approval in 2019, Brukinsa’s stronger ...
SAN MATEO, Calif.--(BUSINESS WIRE)--BeiGene, Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company that intends to change its name to BeOne ...
BeiGene is a BUY due to Tevimbra's approval and Brukinsa's growing sales, leading to anticipated positive earnings in 2025. Q4 and full-year 2024 revenues surged to $1.1B and $3.8B respectively ...
Bank of America Securities analyst David Li maintained a Buy rating on BeiGene (ONC – Research Report) today. The company’s shares closed last ...
SAN MATEO, Calif., February 25, 2025--(BUSINESS WIRE)--BeiGene, Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company that intends to change its name to BeOne Medicines Ltd ...
Good day, everyone. Welcome to BeiGene's Q4 and Full Year 2024 Earnings Call Webcast. All lines have been placed on mute to prevent any background noise. After the speakers' remarks, there will be ...
All information in this presentation is as of the date presented, and BeiGene undertakes no duty to update such information unless required by law.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback